CLDN18 and gastroesophageal junction adenocarcinoma: Another retrospective study using the same assay and cut-off values for CLDN18.2 positivity reported a prevalence of 33.4% in a cohort of 350 evaluable White patients with advanced G/GEJ adenocarcinoma from Italy [12].